Joseph S. Zakrzewski - 10 May 2022 Form 4 Insider Report for Cyteir Therapeutics, Inc.

Role
Director
Signature
/s/ Adam M. Veness, as attorney-in-fact for Joseph Zakrzewski
Issuer symbol
N/A
Transactions as of
10 May 2022
Net transactions value
+$95,077
Form type
4
Filing time
12 May 2022, 16:35:17 UTC
Previous filing
31 Mar 2022
Next filing
16 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CYT Common Stock Purchase $93,377 +49,406 +60% $1.89 131,673 10 May 2022 Direct F1, F2
transaction CYT Common Stock Purchase $1,700 +1,000 +0.76% $1.70 132,673 11 May 2022 Direct F2
holding CYT Common Stock 58,671 10 May 2022 See Footnote F3
holding CYT Common Stock 149,051 10 May 2022 See Footnote F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $1.67 to $2.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F2 55,102 of the shares of common stock held directly and indirectly by the Reporting Person were acquired upon early exercise of an option and are subject to forfeiture until they vest.
F3 Shares held by Z Investments, LLC, of which the Reporting Person is the Managing Director. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest therein.
F4 Shares held by Z3 Trust, of which the Reporting Person is a Trustee. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest therein.